Tapering of Inhaled Steroids Feasible for Asthma Controlled With Benralizumab
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 10, 2024 -- For patients with severe eosinophilic asthma controlled on benralizumab, tapering of inhaled corticosteroids (ICS) is feasible and is not associated with worse asthma control, according to a study published online Dec. 7 in The Lancet.
David J. Jackson, M.P.H., from King's College London, and colleagues conducted a phase 4 study involving adults with severe eosinophilic asthma and a five-item Asthma Control Questionnaire score less than 1.5 and who received at least three consecutive doses of benralizumab before screening. Participants were randomly assigned to taper their high-dose ICS to a medium-dose, low-dose, and as-needed dose (reduction group) or to continue therapy for 32 weeks, followed by 16 weeks of maintenance.
Overall, 168 patients were assigned to the reduction and reference arms (125 and 43, respectively). Ninety-two percent of the 110 patients reduced their ICS-formoterol dose: 15, 17, and 61 percent to medium-dose, low-dose, and as-needed only, respectively. The researchers found that in 96 percent of the patients, the reductions were maintained to week 48; in the tapering group, 91 percent had zero exacerbations during tapering. The rates of adverse events were similar between the groups: 73 and 83 percent in the reduction and reference groups, respectively. A total of 17 patients had serious adverse events: 10 and 12 percent in the reduction and reference groups, respectively. There were no deaths reported.
"Our key finding is that 92 percent of patients were able to successfully reduce their high-dose ICS, with more than 60 percent reducing to anti-inflammatory reliever only without a change in asthma control," the authors write.
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures benralizumab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
FDA Adds Fasenra Indication for Severe Asthma in Children
TUESDAY, April 16, 2024 -- The U.S. Food and Drug Administration has approved an additional indication for Fasenra (benralizumab) as an add-on maintenance treatment for patients...
SARS-CoV-2 Positivity Not Linked to New Asthma Diagnosis in Children
FRIDAY, April 12, 2024 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) positivity in children is not associated with an increased...
Widening of Disparities in Pollution-Attributed Health Burden Observed
THURSDAY, March 14, 2024 -- There has been a widening of racial and ethnic relative disparities in the pollution-attributable health burden within the United States, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.